Biometric covariates and outcome in COVID-19 patients: Are we looking close enough?

Appendix

Influence of baseline values

We checked differential baseline values across the survivors / non-survivors in each subcohort, compared to all survivors and non-survivors. Systematic differential expression in a subcohort compared to all MV patients are given in table 1.

		-	
Bilirubin	Decreased (p < 0.05)	Survivors [Low BMI/high age]	
I:E	Increased (p < 0.05)	Survivors [Low BMI/high age]	
Creatinine	Increased (p < 0.05)	Survivors [Low BMI/high age]	
Tidal volume	Increased (p < 0.05)	Survivors [High BMI/high age]	
SpO2	Increased (p < 0.05)	Non-Survivors	
		[Intermediate BMI/low age]	

Table 1: Baseline values, which are increased / decreased within the respective subcohort

Surprisingly, the only significant difference in subcohort 3 is SpO2 for Non-Survivors despite the highly significant deviation of mortality.

Influence of comorbidities

In analogy to differential levels of baseline diagnostic parameters, we assessed enrichment of comorbidities between survivors and non-survivors for each subcohort compared to survivors / non-survivors in all MV patients.

Comorbidities, which are enriched / suppressed within the survivor/ non-survivor populations of the 6 subcohorts are shown in table 2:

Chronic Heart Failure	Enriched (p < 0.05)	Survivors [High BMI/low age]	
Diabetes Mellitus	Enriched (p < 0.01)	Survivors [High BMI/low age]	
Diseases of blood and blood	Suppressed (p < 0.05)	Non-survivors [Low BMI/high age]	
forming organs			
Diseases of the digestive	Suppressed (p < 0.05)	Non-survivors	
system		[Intermediate BMI/high age]	
Diseases of the digestive	Enriched (p < 0.05)	Non-survivors [High BMI/low age]	
system			
Sepsis	Suppressed (p < 0.05)	Non-survivors [Low BMI/high age]	

Table 2: Comorbidities, which are enriched / suppressed within the respective subcohort

As the enrichment analysis didn't result in neither highly significant enrichments of comorbidities nor difference in diagnostic baseline levels, corrections with respect to multiple testing show no robust significance. Hence, we cannot claim univariate explanations of the observed patterns in morbidity.

Enrichment analysis of comorbidities in non-MV patients compared to MV patients

Assessing the enrichment (Bonferroni-corrected p < 0.01) of comorbidities in MV-survivor / non-survivor population compared to non-MV population, we found comorbidities, which are strongly enriched in MV cohort (independent from survival) compared to non-MV patient cohort:

	Non-MV	MV
Diseases of the blood and blood-	log10(p) = -3.48	log10(p) = -3.73
forming organs		
Diseases of the genitourinary	log10(p) = -2.62	log10(p) = -3.98
system		
Diseases of the skin and	log10(p) = -3.57	log10(p) = -2.22
subcutaneous tissue		
Endocrine, nutritional and	log10(p) = -3.83	log10(p) = -3.3
metabolic diseases		
Symptoms, signs and abnormal	log10(p) = -3.92	log10(p) = -3.98
clinical and laboratory finding		
Sepsis	log10(p) = -4.8	log10(p) = -6.3

Table 3: Enrichment of comorbidities in MV population compared to non-MV population

Apparently, Sepsis is a syndrome, which is highly significantly enriched in MV-patient cohort compared to non-MV cohorts, both for survivors and non-survivors.